Through the years, Rigel has partnered with numerous leading pharmaceutical companies. Current collaborations include, Daiichi Sankyo, AstraZeneca, Aclaris Therapeutics, Grifols, and Kissei, among others.
These collaborations have enabled us to develop assets discovered in Rigel’s laboratories, which further validates our proprietary research platform and capabilities. With many of these organizations, our efforts have led to the addition of new programs or the extension of relationships beyond the scope of the initial agreements.
Along with our commercial business, we continue to explore opportunities to create value through strategic collaborations with pharmaceutical and biotechnology companies that align with our commitment to bringing new therapies to patients with unmet medical needs.